Combination of Laparoscopic Salpingectomy and Endometrial Ablation: A Potentially Underused Procedure

Florencia Greer Polite, MD,1 Mary DeAgostino-Kelly, MD, MPH,1 and Greg J. Marchand, MD2

Abstract

Despite the advantages of a decreased risk of epithelial-cell ovarian cancer and the extremely minimally invasive nature of the procedure, combined salpingectomy and endometrial ablation is a potentially underused procedure in the United States to treat abnormal uterine bleeding and desired sterilization. The lack of utilization of this combined procedure might be based on factors other than clinical considerations, including slow acceptance and adoption of Committee Opinions expressing the value of salpingectomy over sterilization. Committee Opinions and randomized clinical trials have demonstrated the benefit of salpingectomy for sterilization and epithelial-cancer risk reduction, and there could be an additional protection against postablation tubal sterilization syndrome. This Commentary discusses the advantages and rationale for consideration of expanding usage of the combined approach. (J GYNECOL SURG 37:89).

Introduction

A surgical procedure combining endometrial ablation with laparoscopic salpingectomy can have multiple benefits for patients. In select cases, the combination might prevent the need for hysterectomy, and thus avoid the risks and complications that could arise from the more-radical surgical intervention. After seeing high demand, and performing a large number of combination laparoscopic salpingectomy and endometrial ablation procedures in some of their own practices, the current authors analyze the available data on the combination procedure in an effort to determine if the procedure could present an opportunity for increased utilization in clinical practice today.

Although salpingectomy techniques are not new to benign gynecology, since the release of Committee Opinion #6201 in 2015—later replaced by Committee Opinion #774,2 there has been a steady trend toward salpingectomy, rather than tubal ligation, for patients desiring sterilization due to the added benefit of the decreased risk of epithelial-cell ovarian cancer.4,5 Prior to this time, it was likely that most gynecologists considered salpingectomy as the appropriate treatment for ectopic pregnancy and, otherwise, rarely performed salpingectomy outside of correcting failed tubal ligation procedures.6 Although other researchers have advocated for the superiority of salpingectomy over tubal ligation for sterilization,7 the current authors felt that there was no significant literature discussing the utility of combination salpingectomy and endometrial ablation procedures.

Endometrial Ablation

Endometrial ablation is not a perfect surgical remedy for abnormal uterine bleeding (AUB). This procedure has several drawbacks, including a small percentage of women whose bleeding pattern may actually worsen as a result of the procedure.8,9 In addition, researchers have noted that the procedure can have a failure rate that increases with time, making the procedure a less-attractive option for women who are further away from menopause.10 Nonetheless, endometrial ablation can provide many benefits to premenopausal women with heavy menstrual bleeding (HMB),...
including bleeding improvement rates approaching 92% and secondary amenorrhea rates approaching 58% in select populations. As a result, some clinicians may see a combination salpingectomy and ablation procedure to be an alternative to hysterectomy, with only a fraction of the recovery time.

Today, endometrial ablation is the most common procedure performed for treating AUB bleeding in the world, with ~40,000 procedures performed each year in the United States alone. Techniques may vary from labor-intensive “resectoscopic” techniques to commercial nonresectoscopic techniques that are extremely fast and widely performed. The technique is indicated for AUB in pre- or perimenopausal females but, since the technique’s inception, device manufacturers have consistently pushed that definition with direct-to-patient marketing. As a result, it can be difficult for a clinician to determine if a patient who presents desiring an endometrial-ablation procedure truly has HMB that interferes with her quality of life or wishes to cease menstruation. Nevertheless, a very high percentage of women remain satisfied with the procedure postoperatively, with a reported satisfaction rate in the range of 77%–96%. Few complications are reported, with some researchers citing a complication rate of 4.4%. The most-frequent complications reported are hemorrhage (2.4%) and uterine perforation (1.5%).

Salpingectomy

One constant requirement for endometrial ablation remains the need for long-term reliable contraception. As a result, many endometrial-ablation procedures are combined with sterilization procedures to achieve both desired outcomes simultaneously. Previously, a hysteroscopic solution was acceptable with blockage of bilateral fallopian tubes via hysteroscopy in combination with endometrial ablation in a single surgery. With the removal of EssureTM from the U.S. market at the end of 2018, a purely hysteroscopic approach is no longer an option for women in the United States.

Another perceived drawback to salpingectomy is that it could be seen as a less minimally invasive procedure than tubal-occlusion procedures. This is a misconception. In the hands of an experienced surgeon, laparoscopic salpingectomy may actually be a less-invasive surgery than laparoscopic tubal ligation, secondary to the extremely small size of the power instruments used to perform salpingectomy. Both bipolar and ultrasonic-energy devices are available in 5-mm or smaller sizes to complete the procedure. Extremely cosmetic techniques have been described including purely umbilical single-port techniques and 2-port techniques that hide a 5-mm incision below the pubic hairline. The procedure can be performed with reliably low blood loss, and some researchers report operative times as low as 5 minutes. This compares well to many variations of tubal-occlusion techniques, which may require larger, more-invasive entry ports. Some examples include the 8-mm devices required to place FilshieTM and HulkaTM clips for laparoscopic tubal occlusion.

Postablation Tubal Sterilization Syndrome

Adding to the appeal of salpingectomy over tubal ligation is a controversial syndrome called postablation tubal sterilization syndrome (PATSS). Many researchers have written about this syndrome of severe pain, generally starting 5–40 months after endometrial ablation, in patients who have undergone previous tubal ligations. This syndrome was first described by Townsend et al. in 1993, as a syndrome of pain that is theorized as secondary to either a buildup of blood from a small remaining portion of functional endometrium and/or an increase in uterine scarring after ablation. The incidence is not completely understood, and reports vary in limited available studies, with most reporting in the range of 6%–8%, depending on the method of tubal sterilization and the method of endometrial ablation. Some studies performed suggested a higher incidence in specific populations. The current authors were unable to find any published studies or case studies that reported an occurrence of PATSS in any patients who had undergone bilateral salpingectomy, although most salpingectomy techniques include removal of the entire fallopian tube and occlusion of the cornual segment of the fallopian tube at the time of surgery. While hysterectomy remains the gold standard of care for PATSS, many of these patients in the studies were status post endometrial ablation and laparoscopic tubal ligation. With studies citing salpingectomy as a possible treatment for PATSS, it stands to reason that laparoscopic bilateral salpingectomy could prevent the development of PATSS.

Conclusions

Given the multiple advantages of the combination of laparoscopic salpingectomy and endometrial ablation, the current authors believe this combined approach is a widely underused surgery and, in some areas, could become the most-common surgery performed by gynecologic surgeons. When considering the multiple benefits, including sterility, treatment of AUB, and a decreased lifetime risk of epithelial-cell ovarian cancer, this minimally invasive technique should be included in the counseling options for appropriate patients.

References

1. American College of Obstetricians and Gynecologists (ACOG). Salpingectomy for ovarian cancer prevention: ACOG Committee Opinion No. 620. Obstet Gynecol 2015;125:279.
2. American College of Obstetricians and Gynecologists (ACOG). Opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention: ACOG Committee Opinion No. 774. Obstet Gynecol 2019;133:e279.
3. Hicks-Courant KD. Growth in salpingectomy rates in the United States since 2000. Am J Obstet Gynecol 2016;215:666.
4. Madsen C, Baandrup L, Dehldendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: A nationwide case-control study. Acta Obstet Gynecol Scand 2015;94:86.
5. Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts, DS, Lu KH. Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res 2015;8:342.
6. Ercan CM, Sakinci M, Ceyhan ST, Coksuer H, Keskin U, Karasahin KE, Baser I. Recurrent intrauterine pregnancy due to tubal recanalization after tubal sterilization by Pomeroy technique. Eastern J Med 2013;18:195.
7. McAlpine JN, Hanley GE, Woo MM, et al.; British, Ovarian Cancer Research Program of British Columbia. Opportunistic salpingectomy: Uptake, risks, and complications of a regional initiative for ovarian cancer prevention. American J Obstet Gynecol 2014;210:471-e1.

8. Rosati M, Vigone A, Capobianco F, Surico D, Amoruso E, Surico N. Long-term outcome of hysteroscopic endometrial ablation without endometrial preparation. Eur J Obstet Gynecol Reprod Biol 2008;138:222.

9. Martyn P, Allan B. Long-term follow-up of endometrial ablation. J Am Assoc Gynecol Laparosc 1998;5:115.

10. Shamonki MI, Ziegler WF, Badger GJ, Sites CK. Prediction of endometrial ablation success according to perio-perative findings. Am J Obstet Gynecol 2000;182:1005.

11. Baggish MS, Sze EH. Endometrial ablation: A series of 568 patients treated over an 11-year period. Am J Obstet Gynecol 1996;174:908.

12. Neuwirth RS, Loffer FD, Trenhaile T, Levin B. The incidence of endometrial cancer after endometrial ablation in a low-risk population. J Am Assoc Gynecol Laparosc. 2004;11:492.

13. Abbott J, Hawe J, Hunter D, Garry R. A double-blind randomized trial comparing the Cavaterm™ and the NovaSure™ endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertil Steril 2003;80:203.

14. Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA). FDA Activities: Essure. Online document at: www.fda.gov/medical-devices/essure-permanent-birth-control/fda-activities-essure Accessed October 13, 2019.

15. Marchand G, Sainz K. Two port laparoscopic salpingectomy: A five-minute procedure that decreases the risk of ovarian cancer for a lifetime [presentation]. American College of Surgeons Clinical Congress. San Diego, October 24, 2017.

16. Shiber L, Pasic RP. Tissue retrieval in laparoscopic surgery. In: Practical Manual of Minimally Invasive Gynecologic and Robotic Surgery. Boca Raton, FL: CRC Press, 2018:137.

17. Lieberman BA. A clip applicator for laparoscopic sterilization. Fertil Steril 1976;27:1036.

18. Townsend DE, McCausland V, McCausland A, Fields G, Kauffman K. Post-ablation-tubal sterilization syndrome. Obstet Gynecol 1993;82:422.

19. Sharp HT. Endometrial ablation: Postoperative complications. Am J Obstet Gynecol 2012;207:242.

20. Tam T, Elgar C, Jirschele K, Lombard E. post-ablation tubal sterilization syndrome (PATSS) following Novasure endometrial ablation: Two case reports and review of literature. J Minim Invasive Gynecol 2012;19(suppl):S112.

21. Nichols JL, Gordon TO, and Bieber EJ. Postablation tubal sterilization syndrome with hematometra after thermal balloon ablation. J Gynecol Surg 2009;25:17.